問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of Dermatology

更新時間:2024-02-21

劉威廷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2025-03-01 - 2027-08-31

Phase II

Active
A single-therapy, multicenter, repeated-dose phase 2 trial was conducted to evaluate the safety of OBI-858 in subjects with moderate to severe frown lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2024-02-01 - 2028-03-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-11-03 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2028-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-01-01 - 2027-05-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2025-06-30 - 2027-07-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2029-08-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2028-04-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites